Brain-chip startup Neuralink has received its first human patient and is recovering well, according to its founder Elon Musk. The company's initial results show promising neuron spike detection, which are activity by neurons that use electrical and chemical signals to send information around the brain and to the body. The U.S. Food and Drug Administration granted Neuralink clearance last year to conduct its first trial to test its implant on humans, a critical milestone in the startup's ambitions to help patients overcome paralysis and neurological conditions. The study uses a robot to surgically place a brain-computer interface (BCI) implant in a region of the brain that controls the intention to move. The implants' "ultra-fine" threads help transmit signals in participants' brains. Neuralink's first product, Telepathy, is set to launch in the PRIME Study, a trial assessing the safety of its wireless brain-computer interface implant and surgical robot, amid scrutiny from the SEC.